Cationically modified inhalable nintedanib niosomes: enhancing therapeutic activity against non-small-cell lung cancer NNM-2022-0045 Suppl file
Aim: This study was designed to develop and test nintedanib-loaded niosomes as inhalable carriers for
enhancing its therapeutic efficacy via localized drug accumulation and addressing issues such as low
bioavailability and severe toxicity. Methods: Niosomes were prepared by thin-film hydration method
and were evaluated for in vitro therapeutic effectiveness in lung cancer cells. Results: The optimized
niosomal formulation displayed optimized vesicle size, controlled and extended release of drug, and
efficient aerodynamic properties indicating its suitability as an aerosolized formulation. In vitro studies
revealed significantly superior cytotoxicity of nintedanib-loaded niosomes which was further validated
by 3D spheroids. Conclusion: These findings establish the effectiveness of niosomes as inhalable delivery
carriers which could serve as a promising strategy for delivery of nintedanib to treat several lung cancers.